The University of North Carolina at Chapel Hill

Biogen Idec Ma Inc.

Jenny P-y Ting

Jonathan A Harton

Brian P O'Connor

So-Young Eun

Zhengmao Ye

Michael W Linhoff

Jeffrey L Browning

Robert E Johnston

Eric M Bachelder

Michael Andrew Collier

Brandon Johnson

Gene H MacDonald

Kristy Ainslie

Brian J Conti

Jinghua Zhang

Ning Cheng

Xin-sheng Zhu

Christopher B Moore

Brian K Martin

Hao Guo

Willie June Brickey

Haitao Wen

Cathryn Julia Robbins

Robert Junkins

Matthew Gallovic

Kristi L Williams

Provided herein are methods of mitigating and/or preventing side effects from chemotherapy and/or radiotherapy in a subject by administering a therapeutically effective amount of a toll-like receptor 2/6 (TLR 2/6) ligand, including fibroblast-stimulating lipopeptide 1 (FSL-1). Methods of treating and/or preventing gastrointestinal disorders are also disclosed. Additionally, methods of increasing granulocyte colony-stimulating factor (G-CSF) production in a subject undergoing a medical treatment, including administering FSL-1 compositions, are provided.

Methods and treatments using toll-like receptor agonists to mitigate hematopoietic myeloid loss, increase gastrointestinal recovery and reduce tumor growth

The present invention provides a composition comprising a) a polyacetal polymer, a polyester polymer and/or a biodegradable polymer; b) a cyclic dinucleotide; and c) an antigen and/or an antibody, as well as methods of using same.

Methods and compositions for inducing an immune response

The present invention provides methods of reducing or enhancing T cell activation and/or B cell activation in a subject, comprising administering to a subject an effective amount of an inhibitor or enhancer, respectively, of Semaphorin 6D (Sema6D) activity on T cells and/or B cells.

Methods and compositions for modulating T cell and/or B cell activation

The present invention provides a method of treating an immune-related disorder in a subject, comprising administering to the subject an effective amount of an inhibitor of plexin-A4 activity, which results in reducing the plexin-A4 activity in the subject, and thereby treating the immune-related disorder. Inhibitors of plexin-A4 activity include, for example, plexin-A4 antibodies and plexin-A4 fusion proteins. The present invention further provides a method of treating an immune-related disorder in a subject, comprising administering to the subject an effective amount of an inhibitor of semaphorin-3A (Sema3A) activity, which results in reducing the Sema3A activity in the subject, thereby treating the immune-related disorder. Inhibitors of Sema3A activity include, for example, Sema3A antibodies and Sema3A fusion proteins.

Methods and compositions for the treatment of immune disorders

Methods of treating a demyelinating disorder using inhibitors of the lymphotoxin pathway.

Treatment of demyelinating disorders with soluble lymphotoxin-&#x3b2;-receptor

The present invention relates to a new family of structurally and functionally related nucleic acids and proteins, designed the CATERPILLER family, which is characterized by landmark structural motifs including a nucleotide binding domain and leucine-rich repeat domains.

Caterpiller gene family

The present invention provides methods of preventing and/or treating cancers (including tumors). In one preferred embodiment, the invention is practiced to induce regression of an existing cancer or tumor and/or to prevent metastasis and/or to prevent growth of metastatic nodules. In other preferred embodiments, the invention may be used as a prophylaxis to prevent the development of primary cancers through a childhood or adult vaccination program against specific tumor antigens for cancers with high incidences. In an alternate preferred embodiment, the present invention provides methods of establishing an immune response against a universal artificial tumor antigen through a childhood or adult vaccine program, thus providing a long-term immune response that can be utilized at any point to treat any cancer which develops later in life. The present invention also provides cancer and tumor cells stably expressing an artificial antigen, preferably an artificial cell-surface antigen.

Methods and modified cells for the treatment of cancer

Growing community of inventors

Chapel Hill, NC, United States of America

Jenny P-y Ting